DNA binding domain mutational status and rituximab-based treatment are independent prognostic factors for pediatric Burkitt lymphoma patients stratification.
Martire G, Lovisa F, Carraro E, Rizzato D, Cesaro S, Mura RMaria, Tondo A, Bertolin C, Boaretto F, Salviati L, et al. DNA binding domain mutational status and rituximab-based treatment are independent prognostic factors for pediatric Burkitt lymphoma patients stratification. Haematologica. 2024.